Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845429 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 729
- Enrollment target
NCT00845429: Completed Phase 2 study, sponsored by Sanofi.
NCT00845429 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 729 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (448% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00845429, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 729 participants
- Enrollment target
Study Summary
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Interventions
- BIOLOGICAL Influenza virus vaccine - cell based (2007-2008 Formulation)
- BIOLOGICAL Influenza virus vaccine - cell-based (2007-2008 Formulation)
- BIOLOGICAL Influenza virus vaccine (2007-2008 Formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00845429 record still lists
NCT00845429 is an interventional study that assigns participants to a tested intervention. The registered 729 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (448% higher).
The record links to 0 conditions, and to 3 interventions - of which Influenza virus vaccine - cell based (2007-2008 Formulation) is the first listed.
NCT00845429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00845429 about?
NCT00845429 is a clinical study titled "Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects". Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational ce...
What is the current status of trial NCT00845429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 729 participants. The study started on 2007-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00845429?
The interventions under investigation include: Influenza virus vaccine - cell based (2007-2008 Formulation) (BIOLOGICAL), Influenza virus vaccine - cell-based (2007-2008 Formulation) (BIOLOGICAL), Influenza virus vaccine (2007-2008 Formulation) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00845429?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00845429's enrollment target sits among peer trials
729 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia